Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Alice Gosselin"'
Autor:
Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Sylvaine Cartot-Cotton, Patrick Cohen, Séverine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E. Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
There is a need for potent and non-toxic estrogen receptor (ER) antagonists to overcome the limitations of existing endocrine therapies. Here the authors report the results from Arm 1 of the Phase 1/2 study (AMEERA-1) among postmenopausal women with
Externí odkaz:
https://doaj.org/article/896c8c572eae40909c4db5b12e799b6b
Autor:
Nicolas Boissel, Patrice Chevallier, Vadim Doronin, Laimonas Griskevicius, Alexey Maschan, James McCloskey, Alessandro Rambaldi, Giuseppe Rossi, Andrey Sokolov, Ulla Wartiovaara‐Kautto, Corina Oprea, Giovanni Abbadessa, Alice Gosselin, Sandrine Macé, Xavier Thomas
Publikováno v:
Cancer Medicine, Vol 11, Iss 5, Pp 1292-1298 (2022)
Abstract The poor prognosis of acute T‐cell lymphoblastic leukemia (T‐ALL) and T‐cell lymphoblastic lymphoma (T‐LBL) in older adults and patients with relapsed/refractory illness is an unmet clinical need, as there is no defined standard of c
Externí odkaz:
https://doaj.org/article/8eb438a3278541aab472cb141756c479
Autor:
Paolo A Ascierto, Giovanni Abbadessa, Brigitte Demers, PARK John, Adyb Baakili, Rao Saleem, Alice Gosselin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/35b3bb6d7ccb407493633e280e9d64ff
Autor:
Sarat Chandarlapaty, Hannah M Linden, Patrick Neven, Katarina Petrakova, Aditya Bardia, Peter Kabos, Sofia Braga, Valentina Boni, Alice Gosselin, Marina Celanovic, Patrick Cohen, Gautier Paux, Vasiliki Pelekanou, Nils Ternès, Joon Sang Lee, Mario Campone
Publikováno v:
Cancer Research. 82:P1-17
Background: In Arm 2 of the ongoing AMEERA-1 trial (NCT03284957), amcenestrant, an optimized oral SERD combined with the CDK4/6 inhibitor (CDK4/6i) palbociclib demonstrated favorable safety and encouraging antitumor activity among patients with endoc
Autor:
Mario Campone, Sarat Chandarlapaty, Aditya Bardia, Patrick Neven, Katarina Petrakova, Peter Kabos, Valentina Boni, Sofia Braga, Marina Celanovic, Patrick Cohen, Alice Gosselin, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Hannah Linden
Publikováno v:
Cancer Research. 82:OT2-11
Background Endocrine therapy in combination with a targeted cyclin-dependent kinase (CDK) 4/6 inhibitor is the clinical standard for treatment of ER+/HER2- advanced breast cancer. Amcenestrant (SAR439859) is an optimized oral SERD with potent dual ac
Autor:
Mario Campone, Aditya Bardia, Peter Kabos, Sarat Chandarlapaty, Patrick Neven, Valentina Boni, Simon Lord, Sylvaine Cartot-Cotton, Marina Celanovic, Alice Gosselin, Vasiliki Pelekanou, Hannah M Linden
Publikováno v:
Cancer Research. 82:OT2-11
Background Amcenestrant is an optimized oral SERD with potent dual activity of ER antagonism and degradation resulting in inhibition of ER signaling. Amcenestrant monotherapy or combination with palbociclib showed antitumor activity and a favorable s
Autor:
Mario Campone, Patrick Neven, Katarina Petrakova, Sofia Braga, Marina Celanovic, Patrick Cohen, Alice Gosselin, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Valentina Boni
Publikováno v:
Cancer Research. 82:OT2-11
Background Amcenestrant (SAR439859) is an optimized oral SERD with potent dual activity that antagonizes and degrades the ER, resulting in inhibition of the ER signaling pathway. Amcenestrant, as monotherapy or in combination with palbociclib, has sh
Autor:
Alice Gosselin, Séverine Doroumian, Jeffrey Ming, Gary A. Ulaner, Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Marina Celanovic, Mario Campone
Publikováno v:
Cancer Research. 80:P5-11
Background: Selective estrogen receptor (ER) degraders (SERDs) result in ER competitive antagonism and degradation and can block signaling in ER-dependent tumors resistant to other endocrine therapies. This study investigates SAR439859, a potent oral
Autor:
Séverine Doroumian, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Marina Celanovic, Mario Campone, Aditya Bardia, Sarat Chandarlapaty
Publikováno v:
Cancer Research. 80:OT1-04
Background: Anti-estrogen therapy remains the gold standard for prevention and treatment of estrogen receptor-positive (ER+)/human epidermal growth factor receptor-negative (HER2-) breast cancer. However, resistance to anti-estrogen therapy is often
Autor:
Robert Roebling, Alice Gosselin, Florence H. Yong, Li Wang, Jeen Liu, Jessica Lim, Rosalind Walley, Lanju Zhang, Jiacheng Yuan, Nicky Best, Kert Viele
Publikováno v:
Therapeutic Innovation & Regulatory Science. 54:850-860
Historical data have been used to augment or replace control arms in some rare disease and pediatric clinical trials. With greater availability of historical data and new methodology such as dynamic borrowing, the inclusion of historical data in clin